European Medicines Agency recommends Betalutin® (177Lu lilotomab satetraxetan) be granted orphan drug designation for the treatment of marginal zone lymphoma

In the LYMRIT 37-01 Phase 1/2a trial, once-daily administration of Betalutin® was associated with a 78% overall response rate and a 44% complete response rate in a heavily-pre-treated group of patients with advanced marginal zone lymphoma (n=9).


Biospace Inc.